Skip to main content

Table 1 Baseline characteristics of asthma patients from the Netherlands Epidemiology of Obesity study (n = 472)

From: Pulmonary function, exhaled nitric oxide and symptoms in asthma patients with obesity: a cross-sectional study

 

BMI < 30 kg/m2

BMI ≥ 30 kg/m2

Difference (95% CI)a

n = 224

n = 248

Age in years, mean (SD)

55.4 (5.9)

54.9 (6.3)

−0.5 (−1.6, 0.6)

Sex, n (% men)

98 (44)

87 (35)

8.7 (−0.1, 17.5)

Height in meters, mean (SD)

1.7 (0.1)

1.7 (0.1)

−0.0 (−0.0, 0.0)

BMI in kg/m2, mean (SD)b

27.1 (2.4)

34.9 (4.4)

7.8 (7.2, 8.5)

Smoking

  

1.3 (−10.5, 13.2)

 Never, n (%)

83 (37)

94 (38)

 

 Former, n (%)

117 (52)

122 (49)

 

 Current, n (%)

24 (11)

32 (13)

 

Alcohol intake in g/d, mean (SD)b

15.6 (16.4)

11.4 (15.3)

−3.2 (−6.1, −0.3)

Ethnicity, n (% Caucasian)

208 (93)

235 (95)

1.9 (−2.5, 6.3)

Education, n (% high)

98 (44)

80 (32)

−11.5 (−20.3, −2.7)

Physical activity MET h/week, mean (SD)b

38.7 (35.5)

31.4 (30.8)

−7.3 (−13.4, −1.3)

Medication

 SABA, n (%)

34 (15)

49 (20)

4.6 (−2.3, 11.4)

 LABA, n (%)

8 (4)

11 (4)

0.9 (−2.7, 4.4)

 SAMA, n (%)

1 (1)

7 (3)

2.4 (1.2, 4.6)

 LAMA, n (%)

12 (5)

12 (5)

0.5 (−4.5, 3.5)

 ICS, n (%)

41 (18)

41 (17)

−1.8 (−8.7, 5.1)

 Combination LABA + ICS, n (%)

71 (32)

84 (34)

2.2 (−6.3, 10.7)

Asthma duration in years, mean (SD)b

19.4 (18)

20.5 (18.1)

1.1 (−2.1, 4.4)

  1. BMI body mass index, g/d gram/day, MET metabolic equivalent of tasks, SABA short-acting beta-agonists, LABA long-acting beta-agonists, SAMA short-acting muscarinic antagonists, LAMA long-acting β2-adrenergic antagonists, ICS inhalation corticosteroids
  2. aDifferences are presented as difference in means for continuous variables and difference in percentage for categorical variables
  3. bLinear regression analyses with robust standard errors are used for dichotomous variables and non-normally distributed variables